Clinical usefulness of the Oxford classification in determining immunosuppressive treatment in IgA nephropathy

References

• Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002;347:738–48.
   PubMed Web of Science ®Google Scholar
• Collins AJ, Foley RN, Gilbertson DT, Chen SC. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl (2011). 2015;5:2–7.
   PubMed Web of Science ®Google Scholar
• Jin DC, Yun SR, Lee SW, Han SW, Kim W, Park J, et al. Lessons from 30 years’ data of Korean end-stage renal disease registry, 1985–2015. Kidney Res Clin Pract. 2015;34:132–9.
   PubMedGoogle Scholar
• D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36:227–37.
   PubMed Web of Science ®Google Scholar
• Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754–62.
   PubMed Web of Science ®Google Scholar
• Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int. 2006;69:1939–44.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines – application to the individual patient. Kidney Int. 2012;82:840–56.
   PubMed Web of Science ®Google Scholar
• Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373:2225–36.
   PubMed Web of Science ®Google Scholar
• Shima Y, Nakanishi K, Kamei K, Togawa H, Nozu K, Tanaka R, et al. Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy. Nephrol Dial Transplant. 2011;26:163–9.
   PubMed Web of Science ®Google Scholar
• Shin JH, Lee JE, Park JH, Lim S, Jang HR, Kwon GY, et al. The effects of cytotoxic therapy in progressive IgA nephropathy. Ann Med. 2016;48:171–81.
   PubMed Web of Science ®Google Scholar
• Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534–45.
   PubMed Web of Science ®Google Scholar
• Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N, Massat AE, et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int. 2011;80:310–17.
   PubMed Web of Science ®Google Scholar
• Coppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, Cook HT, et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int. 2010;77:921–7.
   PubMed Web of Science ®Google Scholar
• Alamartine E, Sauron C, Laurent B, Sury A, Seffert A, Mariat C. The use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol. 2011;6:2384–8.
   PubMed Web of Science ®Google Scholar
• Katafuchi R, Ninomiya T, Nagata M, Mitsuiki K, Hirakata H. Validation study of Oxford classification of IgA nephropathy: the significance of extracapillary proliferation. Clin J Am Soc Nephrol. 2011;6:2806–13.
   PubMed Web of Science ®Google Scholar
• Shi SF, Wang SX, Jiang L, Lv JC, Liu LJ, Chen YQ, et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the Oxford classification. Clin J Am Soc Nephrol. 2011;6:2175–84.
   PubMed Web of Science ®Google Scholar
• Kang SH, Choi SR, Park HS, Lee JY, Sun IO, Hwang HS, et al. The Oxford classification as a predictor of prognosis in patients with IgA nephropathy. Nephrol Dial Transplant. 2012;27:252–8.
   PubMed Web of Science ®Google Scholar
• Zeng CH, Le W, Ni Z, Zhang M, Miao L, Luo P, et al. A multicenter application and evaluation of the Oxford classification of IgA nephropathy in adult Chinese patients. Am J Kidney Dis. 2012;60:812–20.
   PubMed Web of Science ®Google Scholar
• Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86:828–36.
   PubMed Web of Science ®Google Scholar
• Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study. J Am Soc Nephrol. 2015;26:2248–58.
   PubMed Web of Science ®Google Scholar
• Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, et al. The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int. 2016;89:167–75.
   PubMed Web of Science ®Google Scholar
• Lv J, Shi S, Xu D, Zhang H, Troyanov S, Cattran DC, et al. Evaluation of the Oxford classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2013;62:891–9.
   PubMed Web of Science ®Google Scholar
• Park KS, Han SH, Kie JH, Nam KH, Lee MJ, Lim BJ, et al. Comparison of the Haas and the Oxford classifications for prediction of renal outcome in patients with IgA nephropathy. Hum Pathol. 2014;45:236–43.
   PubMed Web of Science ®Google Scholar
• Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883–7.
   PubMed Web of Science ®Google Scholar
• Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15:157–63.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
   PubMed Web of Science ®Google Scholar
• Dekker FW, de Mutsert R, van Dijk PC, Zoccali C, Jager KJ. Survival analysis: time-dependent effects and time-varying risk factors. Kidney Int. 2008;74:994–7.
   PubMed Web of Science ®Google Scholar
• Thomas L, Reyes EM. Tutorial: survival estimation for Cox regression models with time-varying coefficients using SAS and R. J Stat Softw. 2014;61.
   Web of Science ®Google Scholar
• Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. JAMA. 2001;286:1187–94.
   PubMed Web of Science ®Google Scholar
• Han SH, Ahn SV, Yun JY, Tranaeus A, Han DS. Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions. Am J Kidney Dis. 2009;54:711–20.
   PubMed Web of Science ®Google Scholar
• Haas M, Reich HN. Morphologic markers of progressive immunoglobulin A nephropathy. Adv Chronic Kidney Dis. 2012;19:107–13.
   PubMed Web of Science ®Google Scholar
• Barbour SJ, Reich HN. Risk stratification of patients with IgA nephropathy. Am J Kidney Dis. 2012;59:865–73.
   PubMed Web of Science ®Google Scholar
• Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303:423–9.
   PubMed Web of Science ®Google Scholar
• Gutierrez E, Zamora I, Ballarin JA, Arce Y, Jimenez S, Quereda C, et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol. 2012;23:1753–60.
   PubMed Web of Science ®Google Scholar
• Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368:2402–14.
   PubMed Web of Science ®Google Scholar
• Oruc Z, Oblet C, Boumediene A, Druilhe A, Pascal V, Le Rumeur E, et al. IgA structure variations associate with immune stimulations and IgA mesangial deposition. J Am Soc Nephrol. 2016;27:2748–61.
   PubMed Web of Science ®Google Scholar
• Lai KN, Leung JC, Chan LY, Saleem MA, Mathieson PW, Tam KY, et al. Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol Dial Transplant. 2009;24:62–72.
   PubMed Web of Science ®Google Scholar
• Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009;24:3694–701.
   PubMed Web of Science ®Google Scholar
• Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2009;53:26–32.
   PubMed Web of Science ®Google Scholar
• Le W, Zeng CH, Liu Z, Liu D, Yang Q, Lin RX, et al. Validation of the Oxford classification of IgA nephropathy for pediatric patients from China. BMC Nephrol. 2012;13:158.
   PubMed Web of Science ®Google Scholar
• Lee MJ, Kim SJ, Oh HJ, Ko KI, Koo HM, Kim CH, et al. Clinical implication of crescentic lesions in immunoglobulin A nephropathy. Nephrol Dial Transplant. 2014;29:356–64.
   PubMed Web of Science ®Google Scholar
• Nam KH, Kie JH, Lee MJ, Chang TI, Kang EW, Kim DW, et al. Optimal proteinuria target for renoprotection in patients with IgA nephropathy. PLoS One. 2014;9:e101935.
   Google Scholar